Last $6.42 USD
Change Today 0.00 / 0.00%
Volume 0.0
ABCZF On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
OTC US
As of 8:10 PM 11/7/14 All times are local (Market data is delayed by at least 15 minutes).

abcam plc (ABCZF) Snapshot

Open
$6.42
Previous Close
$6.42
Day High
$6.42
Day Low
$6.42
52 Week High
01/30/14 - $8.53
52 Week Low
10/10/14 - $6.09
Market Cap
1.3B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
200.8M
EX-Date
11/6/14
P/E TM
--
Dividend
$8.84
Dividend Yield
2.15%
Current Stock Chart for ABCAM PLC (ABCZF)

Related News

No related news articles were found.

abcam plc (ABCZF) Related Businessweek News

No Related Businessweek News Found

abcam plc (ABCZF) Details

Abcam plc, through its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, tools and reagents, and immunoassays. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, drug discovery products and services, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company sells its products primarily through the Internet. Abcam plc was founded in 1998 and is based in Cambridge, the United Kingdom.

740 Employees
Last Reported Date: 10/4/14
Founded in 1998

abcam plc (ABCZF) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 185.0K GBP
Co-Founder, Deputy Chairman and Member of Exe...
Total Annual Compensation: 628.0K GBP
Chief Financial Officer, Company Secretary, D...
Total Annual Compensation: 478.0K GBP
Chief Operating Officer, Director and Member ...
Total Annual Compensation: 481.0K GBP
Compensation as of Fiscal Year 2014.

abcam plc (ABCZF) Key Developments

Peter Keen Ceases to Be Non-Executive Director of ABCAM PLC

The Biotech Growth Trust PLC announced that Mr. Peter Keen, non-executive Director, ceased to be a non-executive Director of ABCAM PLC with effect from November 3, 2014.

Abcam Plc, Annual General Meeting, Nov 03, 2014

Abcam Plc, Annual General Meeting, Nov 03, 2014., at 11:00 GMT Standard Time. Location: 330 Cambridge Science Park. Agenda: To receive and adopt the report of the Directors and the financial statements together with auditor's report for the year ended 30 June 2014; to declare a final dividend; to approve the annual report on remuneration for the year ended 30 June 2014 and accounts for the year ended 30 June 2014; to approve the directors' remuneration policy of the annual report and accounts for the year ended 30 June 2014; to re-appoint PricewaterhouseCoopers LLP as auditor and to authorise the Directors to determine their remuneration; to elect Alan Hirzel as a Director; to elect Louise Patten as a Director; to re-elect Jim Warwick as a Director; to approve the proposed amendment to the Abcam 2005 Share Option Scheme and to authorise the Directors to do all such things as may be necessary to carry the same into effect; to exercise all the powers of the company to allot shares in the company; to allot equity securities; and to make market purchases.

Abcam Plc Reports Unaudited Consolidated Earnings Results and Parent Cash Flow Results for the Year Ended June 30, 2014; Proposes Interim and Final Dividend of the Year Ended June 30, 2014, Payable on November 28, 2014; Opens a New Office in Shanghai, China

Abcam Plc reported unaudited consolidated earnings results and parent cash flow results for the year ended June 30, 2014. For the year, on consolidated basis, the company's revenue was £127.954 million compared to £122.206 million a year ago. Operating profit was £43.313 million compared to £42.848 million a year ago. Profit before tax was £43.551 million compared to £42.894 million a year ago. Profit for the year attributable to shareholders was £34.045 million or 17.02 pence per diluted share compared to £32.658 million or 16.34 pence per diluted share a year ago. Adjusted operating profit was £46.578 million compared to £46.530 million a year ago. Adjusted profit before tax was £46.816 million compared to £46.576 million a year ago. Net cash inflow from operating activities was £41.298 million compared to £39.434 million a year ago. Purchase of property, plant and equipment was £3.828 million compared to £3.675 million a year ago. Purchase of intangible assets was £3.647 million compared to £3.548 million a year ago. Adjusted profit after tax was £36.119 million or 18.06 pence per diluted share compared to £35.124 million or 17.57 pence per diluted share a year ago. For the year, on parent basis, the company's net cash inflow from operating activities was £39.230 million compared to £25.022 million a year ago. Purchase of property, plant and equipment was £1.500 million compared to £0.963 million a year ago. Purchase of intangible assets was £3.492 million compared to £3.513 million a year ago. The board of company is proposing a final dividend of 5.62 pence per share, which when added to the interim dividend of 2.13 pence represents an increase of 10.1% for the year as a whole. Subject to shareholder approval the final dividend will be paid on November 28, 2014 to shareholders on the register on November 7, 2014. The company opened a new office in Shanghai, China, providing greater access to local markets and improving the consumer experience.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABCZF:US $6.42 USD 0.00

ABCZF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.86 USD -0.14
Becton Dickinson and Co $130.38 USD -0.02
Bio-Techne Corp $90.26 USD +0.50
Enzo Biochem Inc $4.48 USD +0.29
Sigma-Aldrich Corp $135.80 USD -0.18
View Industry Companies
 

Industry Analysis

ABCZF

Industry Average

Valuation ABCZF Industry Range
Price/Earnings 21.9x
Price/Sales 5.8x
Price/Book 4.1x
Price/Cash Flow 22.0x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABCAM PLC, please visit www.abcam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.